Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.001
Schlusskurs vom Vortag:
$0.001
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$13.53M
Nettoeinkommen (Verlust:
$-44.07M
KGV:
0.00
EPS:
-28.1869
Netto-Cashflow:
$-23.86M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.051
Telesis Bio Inc Stock (TBIO) Company Profile
Firmenname
Telesis Bio Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare TBIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.00 | 0 | 13.53M | -44.07M | -23.86M | -28.19 |
ABT
Abbott Laboratories
|
116.13 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.59 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.14 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.86 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.87 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-03-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-03-18 | Herabstufung | Truist | Buy → Hold |
| 2020-10-05 | Eingeleitet | Goldman | Buy |
| 2020-07-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-06 | Eingeleitet | William Blair | Outperform |
| 2020-06-26 | Eingeleitet | SunTrust | Buy |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-06-18 | Eingeleitet | ROTH Capital | Buy |
| 2018-12-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-07-23 | Eingeleitet | Citigroup | Buy |
| 2018-07-23 | Eingeleitet | Evercore ISI | Outperform |
| 2018-07-23 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Telesis Bio Inc Aktie (TBIO) Neueste Nachrichten
Price to sales forward of Telesis Bio, Inc. – OTC:TBIO - TradingView
Telesis Bio, Inc. Revenue Breakdown – OTC:TBIO - TradingView
Enterprise value to EBIT forward of Telesis Bio, Inc. – OTC:TBIO - TradingView
Enterprise value to revenue forward of Telesis Bio, Inc. – OTC:TBIO - TradingView
Price to earnings forward of Telesis Bio, Inc. – OTC:TBIO - TradingView
Telesis BioDNAYStock Price & News - The Motley Fool
If You Invested $1,000 in TRANSLATE BIO, INC. (TBIO) - Stock Titan
Telesis Bio, Inc. Actuals & Estimates (OTC:TBIO) - TradingView
EnPlusOne Biosciences Welcomes Biotech Veteran, Jim Weissman, to Board of Directors - Business Wire
The Global mRNA Synthesis and Manufacturing Market Size - openPR.com
VBIO Stock Price and Chart — NASDAQ:VBIO - TradingView
Enzymatic Deoxyribonucleic Acid (DNA) Synthesis Technology - globenewswire.com
Net current asset value per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
CapEx per share of Telesis Bio, Inc. – OTC:TBIO - TradingView — Track All Markets
Revenue per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
EBITDA per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
EBIT per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
Cash per share of Telesis Bio, Inc. – OTC:TBIO - TradingView
TBIO Stock: A Guide to Telesis Bio, Inc. - Bitget
J. Craig Venter launches genomics startup designed to boost diagnostic insights - Fierce Biotech
ITOC Stock Price and Chart — NASDAQ:ITOC - TradingView
Biocryst reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Telesis Bio(TBIO) Stock Options Chain | Quotes & News - Moomoo
Telesis Bio Inks Regeneron Deal - sdbj.com
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - Insider Monkey
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
TRANSLATE BIO (TBIO) Stock Price, News & Analysis - Stock Titan
Telesis Bio Bullish on Future After Whirlwind Year - sdbj.com
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Business Wire
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
Top ScanTech AI Systems (STAI) Competitors 2026 - MarketBeat
Telesis Bio secures $3 million in promissory notes By Investing.com - Investing.com UK
Telesis Bio Inc. (TBIO) Quarterly 10-Q Report - qz.com
mRNA Synthesis & Manufacturing Market Report 2024-2029, By Product, Service, and Geo - MarketsandMarkets
Technical Analysis of Telesis Bio, Inc. (OTC:TBIO) - TradingView
Telesis Bio Stock Skyrockets after Beckman Coulter Partnership - timothysykes.com
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. - ChartMill
Telesis Bio to delist from Nasdaq by end of September - Investing.com
Telesis Bio reshuffles board, appoints new chairs By Investing.com - Investing.com Australia
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Yuan Yang completed the acquisition of Eton Bioscience, Inc. from Telesis Bio, Inc. - marketscreener.com
VTAK Stock Price and Chart — AMEX:VTAK - TradingView
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results - Stock Titan
DNA Synthesis Market Size, Share | Growth Report [2034] - Fortune Business Insights
Automating DNA Synthesis Boosts Drug Discovery: - Mary Ann Liebert, Inc.
Global White Biotechnology Market Report 2024-2035: Competitive Landscape and Detailed Profiles of Over 380 Key Players in the White Biotechnology SpaceResearchAndMarkets.com - Business Wire
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results - Macau Business
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket - TradingView
Finanzdaten der Telesis Bio Inc-Aktie (TBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.73%
0.41%
Kapitalisierung:
|
Volumen (24h):